NCT02882009View on ClinicalTrials.gov

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

March 22, 2017

Study Completion Date

March 22, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

Gantenerumab

Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.

DRUG

Placebo

Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.

Trial Locations (1)

66219

PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02882009 - A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants | Biotech Hunter | Biotech Hunter